Shares of Pain Therapeutics, Inc. (NASDAQ:PTIE), saw a significant decline in short interest in May. As of May 15th, there was short interest totalling 863,842 shares, a decline of 23.5% from the April 30th total of 1,129,684 shares, AnalystRatingsNetwork.comreports. Approximately 2.3% of the company’s stock are sold short. Based on an average trading volume of 359,662 shares, the short-interest ratio is currently 2.4 days. Pain Therapeutics, Inc. (NASDAQ:PTIE), net profit margin is 72.40% and weekly performance is 12.64%. On last trading day company shares ended up $6.06. Analysts mean target price for the company is $8.00. Pain Therapeutics, Inc. (NASDAQ:PTIE),distance from 50-day simple moving average (SMA50) is 16.25%.
Analysts at Janney Montgomery Scott initiated coverage on shares of Repligen Corporation (NASDAQ:RGEN), in a research report issued to clients and investors on Thursday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $26.00 price target on the stock. Janney Montgomery Scott’s price target indicates a potential upside of 14.49% from the company’s current price. Repligen Corporation (NASDAQ:RGEN), advanced 3.18% in last trading session and ended the day on $22.71. RGEN, Gross Margin is 64.70% and its return on assets is 15.90%. Repligen Corporation (NASDAQ:RGEN), quarterly performance is 77.15%.
Omeros Corporation (NASDAQ:OMER), Director Peter A. Md Demopulos acquired 6,153 shares of the stock in a transaction dated Tuesday, June 24th. The stock was purchased at an average price of $16.20 per share, with a total value of $99,678.60. Following the acquisition, the director now directly owns 181,220 shares in the company, valued at approximately $2,935,764. Omeros Corporation (NASDAQ:OMER), shares moved down 0.69% in last trading session and was closed at $17.35, while trading in range of $16.85 – 18.01. Omeros Corporation (NASDAQ:OMER), year to date (YTD) performance is 53.68%.
PDL BioPharma Inc (NASDAQ:PDLI), was the target of a significant growth in short interest during the month of May. As of May 30th, there was short interest totalling 31,649,801 shares, a growth of 9.7% from the May 15th total of 28,862,804 shares, Stock Ratings News reports. Based on an average daily trading volume, of 1,980,237 shares, the short-interest ratio is presently 16.0 days. Approximately 21.3% of the company’s stock are sold short. PDL BioPharma Inc (NASDAQ:PDLI), ended the last trading day at $9.60. Company weekly volatility is calculated as 1.86% and price to cash ratio as 4.57. PDL BioPharma Inc (NASDAQ:PDLI), showed a negative weekly performance of 1.54%.